2019
DOI: 10.1096/fj.201900423r
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: An apolipoprotein E (APOE) 4 genotype is the most important, common genetic determinant for Alzheimer disease (AD), and female APOE4 carriers present with an increased risk compared with males. The study quantified cortical and hippocampal fatty acid and phospholipid profiles along with select eicosapentaenoic acid (EPA)‐ and docosahexaenoic acid (DHA)‐derived specialized proresolving mediators (SPMs) in 2‐, 9‐, and 18‐mo‐old APOE3 and APOE4 male and female mice. A 10% lower cortical DHA was evident in APOE4 f… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
30
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
9

Relationship

4
5

Authors

Journals

citations
Cited by 21 publications
(32 citation statements)
references
References 51 publications
2
30
0
Order By: Relevance
“…Women in the age range of 65-75 may have a higher increased risk of AD than men [42]. APOE-TR mice exhibit a sex-specific effect of APOE4 on plasma fatty acids [43]. Female APOE4-TR mice had lower DHA/AA in the cortex at 18 months of age (equivalent to 60 years in humans) compared to APOE3-TR mice.…”
Section: Discussionmentioning
confidence: 99%
“…Women in the age range of 65-75 may have a higher increased risk of AD than men [42]. APOE-TR mice exhibit a sex-specific effect of APOE4 on plasma fatty acids [43]. Female APOE4-TR mice had lower DHA/AA in the cortex at 18 months of age (equivalent to 60 years in humans) compared to APOE3-TR mice.…”
Section: Discussionmentioning
confidence: 99%
“…With the accumulation of positive evidence, modulating nutrition could encourage the prevention of AD. Third, since APOEε4 mice reportedly reduced SPM levels [144], research on the relationship among SPMs and APOE, which is highly relevant to AD, could lead to the discovery of a promising prevention strategy. Fourth, although almost all the current methods for measuring neural levels of SPMs are based on the analysis of pathological samples, a noninvasive method of collecting samples with the imaging of magnetic resonance imaging (MRI), positron emission tomography (PET), and single photon emission computed tomography (SPECT) may help to elucidate the dynamics of SPM activity in the brain.…”
Section: Discussionmentioning
confidence: 99%
“…These gaps in our knowledge need to be filled before considering clinical trials with this promising compound in humans. Although microglia‐mediated inflammation has been addressed in AD 5‐7 and decreased SPM levels have been observed in AD brains, 20,22,23 there is a need to untangle the relationship between inflammation and SPMs in more detail. In the present study, using Aβ 42 ‐treated MdM and d‐THP‐1 cells as in vitro models of microglia in AD, MaR1 was shown to have protective effects, including reduced secretion of pro‐inflammatory cytokines and chemokines, improving cell survival, and the attenuation of Aβ 42 ‐induced NF‐κB activation.…”
Section: Discussionmentioning
confidence: 99%
“…Considering the decrease in MaR1 levels in AD, and the promising results from previous in vitro and in vivo studies, 20,23,35 MaR1 is a candidate substance for re‐establishing the failed resolution in AD. However, the molecular mechanisms of action of MaR1 in the brain and in AD are not yet fully known and further studies are necessary before clinical trials in humans can be considered.…”
Section: Introductionmentioning
confidence: 94%